Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Enzalutamide + VIR-5500 |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Enzalutamide | Xtandi | MDV3100|ASP9785 | Hormone - Anti-androgens 59 | Xtandi (enzalutamide) is a second-generation small molecule inhibitor of androgen receptor, thereby resulting in decreased tumor growth (PMID: 24009414, PMID: 25945058). Xtandi (enzalutamide) is FDA-approved for use in patients with castration-resistant prostate cancer, metastatic hormone-sensitive prostate cancer, and non-metastatic castration-sensitive prostate cancer with biochemical recurrence at high risk for metastasis (FDA.gov). |
| VIR-5500 | AMX-500|AMX500|AMX 500|SAR446329|SAR-446329|SAR 446329|VIR5500|VIR 5500 | VIR-5500 (AMX-500) is a dual-masked bispecific T-cell engager that targets FOLH1 (PSMA), which is activated in the tumor microenvironment and potentially induces antitumor activity (J Clin Oncol 44: 16_Suppl, 17). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|